%0 Journal Article
%A Herr, Felix L.
%A Dascalescu, Christian
%A Ebner, Ricarda
%A Schnitzer, Moritz L.
%A Fabritius, Matthias P.
%A Schmid-Tannwald, Christine
%A Zacherl, Mathias J.
%A Wenter, Vera
%A Unterrainer, Lena M.
%A Brendel, Matthias
%A Holzgreve, Adrien
%A Werner, Rudolf A.
%A Auernhammer, Christoph J.
%A Spitzweg, Christine
%A Knösel, Thomas
%A Burkard, Tanja
%A Ricke, Jens
%A Heimer, Maurice M.
%A Sheikh, Gabriel T.
%A Cyran, Clemens C.
%T Association of integrated biomarkers and progression-free survival prediction in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapy
%J Theranostics
%V 15
%N 13
%@ 1838-7640
%C Wyoming, NSW
%I Ivyspring
%M DKFZ-2025-01196
%P 6444 - 6453
%D 2025
%X Integrated biomarkers that predict survival in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET) receiving peptidereceptor radionuclide therapy (PRRT) are still limited. This study aims to identify predictors of progression-free survival (PFS) in patientswith GEP-NET undergoing two cycles of PRRT.Methods: This single-center retrospective study included 178 patients with GEP-NET (G1 and G2) who received at least twoconsecutive cycles of PRRT with [177Lu]Lu-DOTA-TATE and underwent somatostatin receptor (SSTR)-PET/CT before and aftertherapy. At baseline, Krenning score (KS) > 2, clinical, pathological and laboratory parameters were collected and correlated to PFS.Survival predictors were analyzed using univariate and multivariate models. For goodness-of-fit analysis, the Akaike information criterionand Harrell concordance index were determined. To determine the impact on the regression model the Wald-Test was performed.Results: In univariate analysis, KS 3 (vs. KS 4; HR, 2.02; 95
%F PUB:(DE-HGF)16
%9 Journal Article
%R 10.7150/thno.112588
%U https://inrepo02.dkfz.de/record/301997